Cost-effectiveness and HRQOL outcomes of divalproex sodium (Depakote®) in bipolar disorder

References

• Goodwin FK, Jamison KR. Manic- Depressive Illness. Oxford University Press, NY, USA (1990).
   Google Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am. j Psych. 151(12 Suppl), S1—S36 (1994).
   Google Scholar
• Tohen M, Angst J. Epidemiology of bipolar disorder. In: Psychiatric Epidemiology Tsuang MT, Tohen M (Eds). Wiley-Liss, NY, USA, 427–444 (2002).
   Google Scholar
• Kessler RC, McGonagle IKA, Zhao S eta]. Lifetime and 12-month prevalence of DSM III-R psychiatric disorders in the United States. Arch. Gen. Psychiatry51, 8–19 (1994).
   Google Scholar
• Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhoa S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. PTchol Med. 27, 1079–1089 (1997).
   Google Scholar
• •Prevalence estimates of bipolar disorder in the USA based on the National Comorbidity Study.
   Google Scholar
• Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness. Soc. Bychiatry PTchiad: Epidemiol 30, 213–219 (1995).
   PubMed Web of Science ®Google Scholar
• Kleinman LS, Lowin A, Flood E, Gandhi G, Edgell E, Revicki DA. Costs of bipolar disorder. PharmacoEconomics 21,601–622 (2003).
   PubMed Web of Science ®Google Scholar
• •Reviews the economic impact of bipolar disorder.
   Google Scholar
• Revicki DA, Matza L, Flood E, Isserman J, Lloyd A. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. PharmacoEconomics (2003) (In Press).
   Google Scholar
• •Reviews the literature on the quality of life impact of bipolar disorder.
   Google Scholar
• World Health Organization. The World Health Report, 1999. World Health Organization, Geneva, Switzerland (1999).
   Google Scholar
• Dion GL, Tohen M, Anthony WA, Waternaux CS. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp. Com. Psych. 39, 652–657 (1988).
   PubMedGoogle Scholar
• Coryell W Scheftner W, Keller M, Endicott J, Maser J, Merman GL. The enduring psychosocial consequences of mania and depression. Am. j Psych. 150, 720–727 (1993).
   Google Scholar
• Leidy N, Palmer C, Murray M et al. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder: psychometric performance of four self-report measures. j Affect. Dis. 48,207–214 (1998).
   PubMed Web of Science ®Google Scholar
• Keck PE, McElroy SL, Strakowski WM et al Twelve-month outcome of bipolar patients following hospitalization for a manic or mixed episode. A117. I Psych. 155, 646–652 (1998).
   Google Scholar
• Suppes T, Dennehy EB, Swann AC eta]. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.1 Clin. Psych. 63,288-299 (2002).
   Google Scholar
• •Consensus guidelines on medication therapy for bipolar disorder.
   Google Scholar
• Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen. Psych. 48,62–68 (1991).
   Google Scholar
• Freeman TVV, Clothier JL, Pazzaglia P, Lesem MD, Swan AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. I Psych. 149,108–111 (1992).
   Google Scholar
• Bowden CL, Brugger AM, Swann AC et al Efficacy of divalproex sodium vs. lithium and placebo in the treatment of mania. JA/V/A 271,918–924 (1994).
   Google Scholar
• Bowden CL. Efficacy of lithium in mania and maintenance therapy for bipolar disorder. I Clin. Psych. 61 (Suppl. 9), 35–40 (2000).
   Google Scholar
• Bowden CL, Calabrese JR, McLeroy SL eta]. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar disorder. Arch. Gen. Psych. 57,481-489 (2000).
   Google Scholar
• ••Recent placebo-controlled clinical trialcomparing lithium and divalproex sodium over 1 year.
   Google Scholar
• Tohen M, Sanger TM, McElroy SL etal Olanzapine versus placebo in the treatment of acute mania. Am. I Psych. 156,702–709 (1999).
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grudy SL etal Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. Psych. 57,841–849 (2000).
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RVV, Altshuler LL etal Olanzapine versus divalproex in the treatment of acute mania. Am. I Psych. 159,1011–1017 (2002).
   PubMed Web of Science ®Google Scholar
• •• Clinical trial comparing olanzapine and divalproex sodium in acute mania.
   Google Scholar
• Tohen M, Ketter TA, Zarate CA et al Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Aim j Psych. 160, 1263–1271 (2003).
   PubMed Web of Science ®Google Scholar
• •• Clinical trial comparing olanzapine and divalproex sodium for acute mania and long-term follow-up.
   Google Scholar
• Zajecka JM, Weisler R, Sachs G etal A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.j Clin. Psych. 63,1148–1155 (2002).
   Google Scholar
• •• Clinical trial comparing divalproex sodium and olanzapine over 12 weeks for acute mania.
   Google Scholar
• Goodwin FK, Fireman B, Simon GE, Hunkler E, Revicki DA. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAIVIA 290, 1467–1473 (2003).
   Google Scholar
• Unutzer J, Simon GE, Pabiniak C, Bond K, Katon W The use of administrative claims data to assess quality of care in bipolar disorder in a large staff model HMO. Gen. Hasp. Psych. 22,1–10 (2000).
   Google Scholar
• Tohen M, Watemaux CS, Tsuang MT Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psych. 47,1106–1111 (1990).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. A117. I Psych. 152,379-384 (1995).
   Google Scholar
• Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am. j Psych. 152, 1635–1640 (1995).
   PubMed Web of Science ®Google Scholar
• Keller MB, Lavori PW, Coryell W Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. j Nerv. Ment. Dis. 181,238-245 (1993).
   Google Scholar
• Coryell W, Turvey C, Endicott J eta]. Bipolar I affective disorder: predictors of outcome after 15 years. J. Affect. Dis. 50, 109–116 (1998).
   Google Scholar
• Suppes T, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. j Clin. Psych. 61\(Suppl. 9), 23–30 (2000).
   Google Scholar
• Revicki DA, Hirschfeld R, Ahearn A etal. Effectiveness and medical costs of divalproex versus lithium treatment of bipolar disorder: results of a naturalistic clinical trial. (2003) (In Press).
   Google Scholar
• •• Randomized, pragmatic clinical trial comparing lithium and divalproex sodium over 12 months with clinical, health-related quality of life (HRQOL) and medical cost outcomes.
   Google Scholar
• Revicki DA, Paramore LC, Sommerville KW etal Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. j Clin. Psych. 64,288–294 (2003).
   Google Scholar
• ••Clinical trial comparing divalproexsodium and olanzapine over 12 weeks with clinical, HRQOL and medical cost outcomes
   Google Scholar
• Endicott J, Nee J, Harrison etal Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psych. Bull. 29,321–326 (1993).
   Google Scholar
• Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center, MA, USA (1993).
   Google Scholar
• Stewart AL, Ware JE, Sherboume CD etal Psychological distress/well-being and cognitive functioning measures. In: Measuring Functioning and WE-being the Medical Outcomes Stuc Approach. Stewart AL, Ware JE (Eds). Duke University Press, NC, USA (1992).
   Google Scholar
• Revicki DA, Tohen M, Gyulai L etal Telephone versus in-person clinical and health status assessment interviews in bipolar disorder patients. Harv. Rev Bych. 5,75–81 (1997).
   PubMed Web of Science ®Google Scholar
• Keck PE, Nabulsi A, Taylor J. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. j Clin. Psych. 57,213–222 (1996).
   Google Scholar
• •Modeling study estimating the medical costs of lithium and divalproex sodium over 12 months for the treatment of bipolar disorder.
   Google Scholar
• Revicki DA, Luce BR. Methods of pharmacoecnomic evaluation of new medical treatments in psychiatry. Psych. Bull. 31,57–65 (1995).
   Google Scholar
• Namjoshi M, Rajammannar G, Jacobs T etal Economic, clinical and quality of life outcomes associated with olanzapine treatment in mania: results from a randomized clinical trial. j Affect. Dis. 69, 109–118 (2001).
   Google Scholar
• •Evaluates the impact of olanzapine on medical cost, HRQOL and clinical outcomes.
   Google Scholar
• Sanger T, Namjoshi M, Gibson P etal Long-term olanzapine therapy in the stabilization and maintenance treatment of bipolar I disorder: an open label continuation phase study. j Clin. Psych. 62, 273–281 (2001).
   Google Scholar